MEDEZE Stock Overview
Engages in collection and storage of stem cells for use in medication in Thailand, Vietnam, Cambodia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Medeze Group Public Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ฿8.05 |
| 52 Week High | ฿13.80 |
| 52 Week Low | ฿7.45 |
| Beta | 0 |
| 11 Month Change | -25.46% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -28.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| MEDEZE | TH Healthcare | TH Market | |
|---|---|---|---|
| 7D | -0.6% | -2.9% | 0.8% |
| 1Y | n/a | -10.6% | 3.1% |
Return vs Industry: Insufficient data to determine how MEDEZE performed against the TH Healthcare industry.
Return vs Market: Insufficient data to determine how MEDEZE performed against the TH Market.
Price Volatility
| MEDEZE volatility | |
|---|---|
| MEDEZE Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 4.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in TH Market | 10.3% |
| 10% least volatile stocks in TH Market | 2.4% |
Stable Share Price: MEDEZE's share price has been volatile over the past 3 months compared to the TH market.
Volatility Over Time: Insufficient data to determine MEDEZE's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | Veerapol Khemarangsan | www.medezegroup.com |
Medeze Group Public Company Limited engages in collection and storage of stem cells for use in medication in Thailand, Vietnam, Cambodia, and internationally. The company operates through four segments: Stem Cells; Natural Killer Cells; Others; and Sales of Products. It also provides sorting, cultivation, and development of stem cells; testing services to test the performance and count the number of natural killer cells; and research, develops, and collects data on all types of human cellular activities and medical laboratory test.
Medeze Group Public Company Limited Fundamentals Summary
| MEDEZE fundamental statistics | |
|---|---|
| Market cap | ฿8.44b |
| Earnings (TTM) | ฿270.40m |
| Revenue (TTM) | ฿780.07m |
31.8x
P/E Ratio11.0x
P/S RatioIs MEDEZE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEDEZE income statement (TTM) | |
|---|---|
| Revenue | ฿780.07m |
| Cost of Revenue | ฿167.21m |
| Gross Profit | ฿612.85m |
| Other Expenses | ฿342.46m |
| Earnings | ฿270.40m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.25 |
| Gross Margin | 78.56% |
| Net Profit Margin | 34.66% |
| Debt/Equity Ratio | 0% |
How did MEDEZE perform over the long term?
See historical performance and comparison